What class of compound is GLP-2 (Teduglutide-like)?

GLP-2 (Teduglutide-like) is classified as a Intestinotrophic peptide. Within this class, alternative names and analogues include Glucagon-like peptide-2. The class-level pharmacology shapes both the clinical applications and the safety profile; the body composition / training literature treats GLP-2 (Teduglutide-like) alongside its class peers when evaluating relative merits.

What route should I use for GLP-2 (Teduglutide-like)?

GLP-2 (Teduglutide-like) is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

Is GLP-2 (Teduglutide-like) safe during pregnancy or breastfeeding?

GLP-2 (Teduglutide-like), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What does GLP-2 (Teduglutide-like) stack well with?

For body composition / training protocols, GLP-2 (Teduglutide-like) pairs with compounds on complementary pathways: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500. These pairings are selected because they engage independent receptor systems from GLP-2 (Teduglutide-like)'s primary mechanism (GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons), producing additive or synergistic effects rather than receptor competition.

Home/ Compounds/ GLP-2 (Teduglutide-like)

GLP-2 (Teduglutide-like)

Body Composition

For the body-composition and physique community, GLP-2 (Teduglutide-like) is run inside a training-driven framework where the compound supports rather than substitutes for stimulus and nutrition. GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons Stimulates crypt cell proliferation, villus height, and intestinal blood flow. Reduces gut permeability and supports epithelial repair.. The ~7 min native; analogues 1.3-2 hr pharmacokinetic profile determines training-day versus rest-day dosing, while the subq administration shapes injection-site rotation and protocol planning.

Body Composition / Training Applications

HyperplasiaTraining PerformanceBody RecompositionJoint HealthMuscle Endurance

Key Takeaways

Body composition lens: response to GLP-2 (Teduglutide-like) is proportional to training stimulus and nutritional adequacy.
Mechanism: GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons.
Body composition dose: Research dose 0.05 mg/kg/day (teduglutide approved) 1x daily subq via subq; effects visible at week 4-8 with adequate training and protein.
Cycle structure: 8-12 weeks on, 4 weeks off; training-day or daily dosing depending on half-life.
Performance stack partners: IGF-1 LR3, CJC-1295 + Ipamorelin Blend, TB-500.

Body Composition / Training Mechanism

GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons. Stimulates crypt cell proliferation, villus height, and intestinal blood flow. Reduces gut permeability and supports epithelial repair. Body composition relevance of this mechanism depends on which dimension of the anabolic cascade GLP-2 (Teduglutide-like) engages: direct GH/IGF-axis activation, recovery-and-connective-tissue effects, or training-adjacent (sleep, inflammation) layers. The subsections below cover anabolic substrate, recovery window, training-day dosing, and hyperplasia versus hypertrophy.

Anabolic substrate and protein synthesis

GLP-2 (Teduglutide-like)'s relevance to body composition depends on where in the anabolic cascade it acts. It acts on adjacent rather than directly anabolic pathways, but the contribution to recovery, connective tissue, and inflammatory tone produces measurable body-composition effects in trained users. The downstream effect on body composition is dose- and training-dependent.

Recovery window and training frequency

The most reliably reported effect of GLP-2 (Teduglutide-like) in athlete populations is on the recovery window between sessions. Faster connective tissue recovery, better sleep quality, and reduced systemic inflammation translate into more high-quality training days per cycle. This is the practical mechanism by which body composition shifts for most users — not via dramatic acute anabolic effect but via more accumulated quality training.

Training-day versus rest-day dosing

Many peptides in this category respond better to training-day-only versus rest-day-included dosing. GLP-2 (Teduglutide-like) with a ~7 min native; analogues 1.3-2 hr half-life of ~7 min native; analogues 1.3-2 hr is short-lived enough that timing relative to training sessions matters. The practical dosing schedule reflects this.

Body Composition / Training Applications

Fat Loss

The body composition community converges on GLP-2 (Teduglutide-like) for fat loss with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Training Performance

For training performance, GLP-2 (Teduglutide-like) integrates with training programming on a per-session and per-cycle basis. Training-day dosing produces stronger acute effect; rest-day inclusion supports sustained baseline. The protocol pattern reflects training intensity and recovery demand.

Muscle Endurance

Muscle Endurance responds to GLP-2 (Teduglutide-like) with effect sizes proportional to training stimulus and nutritional adequacy. Users running aggressive caloric deficits see reduced response; users in surplus with adequate protein see proportionally larger response. Programming the inputs is half the protocol.

Joint Health

The body composition community converges on GLP-2 (Teduglutide-like) for joint health with reported best-fit cycles of 8–12 weeks. Off-cycle of 4 weeks is standard. Stacking with complementary peptides on different pathways is the typical pattern for advanced users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	Research dose 0.05 mg/kg/day (teduglutide approved)	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	Research dose 1.05 mg/kg/day (teduglutide approved)	4–6 weeks initial cycle
Body Composition focus	SubQ	Research dose 0.05 mg/kg/day (teduglutide approved)	1x daily SubQ
Maintenance phase	SubQ	Research dose 1.05 mg/kg/day (teduglutide approved)	Ongoing with periodic pauses

Dose timing for GLP-2 (Teduglutide-like) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

GLP-2 (Teduglutide-like) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from performance coaches and athletes.

GLP-2 (Teduglutide-like) + IGF-1 LR3: Binds the IGF-1 receptor with full agonist activity. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in body composition / training protocols.
GLP-2 (Teduglutide-like) + CJC-1295 + Ipamorelin Blend: CJC-1295 stimulates the GHRH receptor; ipamorelin stimulates the ghrelin/GHSR receptor. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in body composition / training protocols.
GLP-2 (Teduglutide-like) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in body composition / training protocols.
GLP-2 (Teduglutide-like) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with GLP-2 (Teduglutide-like)'s mechanism in body composition / training protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Teduglutide / Gattex for SBS) Research: Phase III in SBS; off-label gut research

Colorectal polyp surveillance required (long-term mitogenic effects on gut epithelium). Risk of intestinal obstruction. Pancreatitis risk.

Lens-specific safety considerations for body composition / training use of GLP-2 (Teduglutide-like): Colorectal polyp surveillance required (long-term mitogenic effects on gut epithelium). Risk of intestinal obstruction. Pancreatitis risk. Additional body composition / training monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Teduglutide / GLP-2 analogue in short bowel syndrome

PMID 16224019

Supporting

GLP-2 mucosal trophic effects

PMID 21565669

GLP-2 (Teduglutide-like) vs Related Peptides

Compound	Profile	Onset	Best For
GLP-2 (Teduglutide-like)	Intestinotrophic peptide	~7 min native; analogues 1.3-2 hr	Body Composition
IGF-1 LR3	Modified insulin-like growth factor 1	~20-30 hr (vs ~10 min for native IGF-1)	A modified IGF-1 with a 13-amino-acid N-terminal extension and Arg substitution that resists IGFBP binding — extending half-life from 10 minutes to roughly a day
Tesamorelin	Stabilised GHRH analogue	~30 min	An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Can I use GLP-2 (Teduglutide-like) alongside creatine, protein, and standard supplements?

Yes — peptide protocols are fully compatible with the standard supplement stack. Creatine, protein powder, beta-alanine, citrulline, and the like operate on entirely separate mechanisms and are additive. Pre-workout stimulants and high-caffeine intake are also compatible.

Best stack pairing for lean mass?

The canonical lean mass stack pairs GLP-2 (Teduglutide-like) with a complementary GH-axis component, a connective-tissue support peptide, and — in advanced protocols — an anabolic-supportive component. Specific pairings depend on which dimension of body composition is prioritised: pure mass, mass-and-fat-loss, or recovery-focused.

Should I cycle GLP-2 (Teduglutide-like)?

Standard cycle structure for body composition use is 8–12 weeks on, 4 weeks off. Continuous indefinite use is not advised for most compounds in this class; the off-period preserves dose response and reduces cumulative downregulation. Cycle stacking with complementary peptides is common in advanced protocols.

How does GLP-2 (Teduglutide-like) compare to AAS for body composition?

Peptide therapeutics including GLP-2 (Teduglutide-like) produce more modest body composition shifts than anabolic-androgenic steroids and operate on different mechanisms with substantially different side-effect profiles. The compound is most-appropriate for users prioritising long-term sustainability and clean blood work over maximum acute mass.

What is the mechanism of action of GLP-2 (Teduglutide-like)?

GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons. Stimulates crypt cell proliferation, villus height, and intestinal blood flow. Reduces gut permeability and supports epithelial repair. For anabolic and recovery applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: GLP-2 receptor agonist expressed on subepithelial myofibroblasts and enteric neurons. The body composition / training interpretation focuses on the pathway-level detail rather than on any single high-level summary.

How long until I see results from GLP-2 (Teduglutide-like)?

Acute effects from GLP-2 (Teduglutide-like) appear within hours of dosing for receptor-level changes. anabolic and recovery endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Clinical Protocol

Start a GLP-2 (Teduglutide-like) Protocol

Alukard provides physician-supervised body composition protocols with GMP-certified GLP-2 (Teduglutide-like) and GMP-certified compounds and training-aware dosing guidance.

Get Protocol

Quick Facts

Molecular weight: ~3766 Da
Sequence length: 33 aa
Half-life: ~7 min native; analogues 1.3-2 hr
WADA: Not on prohibited list
FDA: Approved (Teduglutide / Gattex for SBS)
Research: Phase III in SBS; off-label gut research

Stack Partners

IGF-1 LR3

CJC-1295 + Ipamorelin Blend

TB-500

BPC-157

Tesamorelin + Ipamorelin Blend

Research Note

All body composition / training applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for GLP-2 (Teduglutide-like) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised body composition protocols

Start Your Body Composition / Training Protocol for GLP-2 (Teduglutide-like)

Alukard provides physician-supervised body composition protocols with GMP-certified compounds and training-aware dosing guidance.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised